Uterine Cancer Flashcards
(11 cards)
What is a new staging system incorporating for early-stage endometrial adenocarcinomas?
Molecular and genomic features
This system helps in determining treatment and prognosis.
What is essential for determining treatment and prognosis in endometrial adenocarcinomas?
Somatic mutation status
This status informs the risk levels associated with different mutations.
What prognosis do POL-E mutants carry?
Good prognosis/lowest risk
POL-E mutations are associated with more favorable outcomes.
What does dMMR carry in terms of prognosis?
Intermediate prognosis
This indicates a moderate level of risk.
What mutations convey the worst prognosis in endometrial adenocarcinomas?
TP53 mutations
TP53 mutations are linked to the highest risk.
Does adjuvant treatment improve survival in low risk, localized disease?
No, it is not recommended
Adjuvant treatment does not provide survival benefits for low-risk patients.
Is adjuvant chemoRT recommended for patients with high risk, localized disease?
Yes, it is recommended
This treatment approach is suggested for those at higher risk.
What is the survival benefit associated with in stage IV disease?
Cytoreductive surgery
This surgical intervention can lead to improved survival rates.
What is the chemotherapy backbone for metastatic endometrial adenocarcinoma?
Carboplatin/paclitaxel
This combination is standard for treating metastatic disease.
Most patients with metastatic disease will receive which treatments?
Carbo/taxol + ICI with pembro or dostarlimab
ICI refers to immune checkpoint inhibitors.
What treatment may some HER2+ patients receive?
Carbo/taxol + trastuzumab
This is targeted therapy for patients with HER2 overexpression.
